INDIANAPOLIS and NEW YORK, July 16, 2026
Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley Inc., a clinical-stage biopharmaceutical company focused on developing rapid-acting therapies for treatment-resistant depression (TRD) and other serious mental health conditions. The acquisition significantly strengthens Lilly’s neuroscience pipeline by adding a portfolio of innovative neuroplastogen-based therapeutics designed to restore neural connectivity rather than simply manage symptoms. The transaction is centered around BPL-003, an investigational intranasal synthetic 5-MeO-DMT therapy that has demonstrated rapid and durable antidepressant effects in clinical studies and has already received U.S. FDA Breakthrough Therapy Designation. Lilly will also gain access to additional late-stage pipeline assets, including VLS-01, currently in Phase 2b development, reinforcing the company’s long-term strategy of delivering transformative therapies for patients with severe psychiatric disorders who have limited treatment options. The acquisition highlights growing industry investment in next-generation neuroscience innovation and reflects increasing confidence in therapies targeting the biological mechanisms underlying mental illness.
Acquisition Accelerates Innovative Depression Therapies
The agreement gives Lilly ownership of a promising portfolio of rapid-acting neuroplastogen therapies developed to address the significant unmet medical need associated with treatment-resistant depression, a condition affecting millions of patients who fail to respond to conventional antidepressants. The lead candidate, BPL-003 (mebufotenin benzoate), is administered as an intranasal therapy and is designed to rapidly restore synaptic plasticity, enabling the brain to rebuild neural connections involved in mood regulation. Clinical data from a Phase 2b study demonstrated meaningful and durable reductions in depressive symptoms following a single clinic visit lasting approximately two hours, with therapeutic benefits extending for several months. In addition to BPL-003, Lilly acquires VLS-01, a buccal film formulation of DMT currently advancing through Phase 2b clinical development, as well as additional discovery-stage neuroscience programs focused on developing next-generation psychiatric therapies. Together, these assets significantly expand Lilly’s leadership in innovative mental health research while complementing its broader neuroscience portfolio.
Strategic Transaction Strengthens Neuroscience Leadership
Under the terms of the agreement, Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, representing an upfront equity value of approximately $2.8 billion, with additional contingent value rights (CVRs) potentially increasing the total transaction value by another $1 billion upon achievement of future clinical and regulatory milestones involving BPL-003 and VLS-01. The acquisition is expected to close during the third quarter of 2026, subject to shareholder approval and customary regulatory conditions. The transaction reflects Lilly’s strategy of investing in clinically validated assets with the potential to transform standards of care across challenging therapeutic areas. By combining AtaiBeckley’s specialized expertise in neuroplasticity with Lilly’s global development capabilities, manufacturing resources, and commercial infrastructure, the companies aim to accelerate the availability of novel therapies for patients living with severe psychiatric illnesses.
Advertisement
Advancing the Future of Precision Psychiatry
Emerging scientific research increasingly suggests that treatment-resistant depression and related psychiatric disorders involve disruptions in synaptic connectivity, making neuroplasticity an attractive therapeutic target. Unlike conventional antidepressants that primarily regulate neurotransmitter activity, AtaiBeckley’s investigational therapies are designed to promote the growth of new neural connections while addressing the underlying biological mechanisms responsible for persistent depressive symptoms. Through this acquisition, Lilly strengthens its commitment to advancing precision neuroscience, expanding its capabilities beyond traditional pharmacology into innovative biologically targeted mental health treatments. As regulatory agencies continue supporting breakthrough psychiatric innovations, the addition of BPL-003, VLS-01, and the broader AtaiBeckley pipeline positions Lilly to play an increasingly important role in transforming the treatment landscape for depression and other complex neuropsychiatric disorders. The acquisition also reinforces broader pharmaceutical industry momentum toward developing rapid-acting therapies capable of delivering durable clinical benefits for patients with high unmet medical needs.
Source: Eli Lilly, AtaiBeckley press release
